1. No category

Media Kit 2012
Drugs Devices Injectables Skin Care Sunscreens
The annual side-by-side comparison
of every product in dermatology
Editor-in-Chief: Perry Robins, MD
Co-Editors:
Kenneth R. Beer, MD
Joseph B. Bikowski, MD
Joel L. Cohen, MD
Mitchel P. Goldman, MD
Mary P. Lupo, MD
Maritza Perez, MD
Neil S. Sadick, MD
Special
Discount Rat
es
for Early Spa
ce
Reservation
Media Kit 2012
FROM THE EDITORS OF JDD
Apr il 2011
ISSN: 1545
• Volume 10
• Issue 4
9616
EDITOR-IN-CHIEF:
Perry Robins, MD
Professor Emeritus of Dermatology
NYU Medical Center, NY
CO-EDITORS:
J DD
OPIC:
SPECIAL T
LIGHT
LASERS AND
SOURCES
the
rfacing for
Laser Resu
page 340
ISSN:Image
1545credit
9616 of Fractional Ablative CO2 Striae
ew
Scars and
y and Revi
, Photoaging,
Clinical Stud
of Rhytides
of y
Treatment
tmentMa
for the Trea
y
erap
toth
B Light Pho
Ultraviolet
iasis
Narrowband
to Severe Psor
limumab Plus
Moderate
Multi-Center
Kenneth R. Beer, MD
Voluntary Assistant Professor
University of Miami, FL
Joseph B. Bikowski, MD
Clinical Professor of Dermatology
Ohio State University, OH
2011 • Vol
ume 10
• Issue 5
Ada
Cream
Fluorouracil
With Topical
ial Therapy
tosis
of Sequent
of Actinic Kera
Assessment
Treatment
Case-Based
-PDT for the
:
Prospective,
0.5% and ALA
vulinic Acid
nole
Ami
Therapy With
todynamic
tiva by Pho
itis Suppura
Results
of Hidraden
Preliminary
Treatment
Laser
ye
ed-D
nm Puls
a Novel 607
hromia With
of
tment of Dysc
and Safety
Laser Trea
e
the Efficacy
to Evaluate
nts Who Hav
Pilot Study
iasis in Patie
ive Cohort
Plaque Psor
bel, Prospect
e to Severe
n-La
erat
limumab
Ope
Mod
An
nt of
onse to Ada
in the Treatme
quate Resp
pt
Ade
erce
an
Etan
Not Had
poreal
a and Extracor
Alph
n
fero
Syndrome
tion With Inter
and Sézary
at in Combina
Fungoides
of Vorinost
e Mycosis
The Efficacy
is in Late Stag
ling?
Photopheres
Class Labe
ciation or a
: A True Asso
retin
Acit
and
Guest Edited
VIEWS
Depression
ELINE PRE
J DD
SPECIAL T
O
PIC:
SKIN OF CO
LOR
RESIDENT
ROUNDS
TRIAL
Image credit page
CLINICAL
Advances
by AndrewPIP
REVIEW
F. Alex
is, MD MPH
456
in the Trea
tment of Kelo
ids
Topical Reti
noids for Pigm
Fillers in the
Joel L. Cohen, MD
Clinical Assistant Professor of Dermatology
University of Colorado, CO
Progressive
Topical Tacr
olimus is Mor
e Effective
ented Skin
Skin of Colo
r Population
Macular Hyp
omelanosis
for Treatme
nt of Vitiligo
Scalp Hyperke
ratosis and
A Survey of
Melasma in
Alopecia in
in Patients
Children of
of Skin of Colo
r
Color
Latin Ame
ricans
Skin Conditio
ns and Con
cerns in Sou
th Asian Ame
ricans: A Com
An Over-the
munity-Based
-Counter Moi
Study
Prescription
sturizer Is
Barrier Crea
as Clinicall
ms in the Trea
y Effective
as, and Mor
tment of Chil
e Cost-Effe
dren With
ctive Than
Randomized
Mild-to-Moder
,
, Controlled
ate Atopic
Trial
Dermatitis
:A
Infliximab
Treatment
for Psoriasis
in 120 Patie
nts on Ther
apy for a Min
RESIDENT
imum of One
ROUNDS
Year: A Revi
CLINICAL
ew
TR
Mitchel P. Goldman, MD
Clinical Professor of Dermatology/Medicine
University of California, CA
IAL REVIEW
PIPELINE
PREVIEWS
Mary P. Lupo, MD
Clinical Professor of Dermatology
Tulane Medical School, LA
Maritza Perez, MD
Director of Cosmetic Dermatology,
St. Luke’s Roosevelt Medical Center, NY
EXCELLENCE
THROUGH
PEER-REVIEW
Neil S. Sadick, MD
Clinical Professor of Dermatology
Weill Medical College of Cornell University, NY
Faculty for The Derm Directory 2012 is subject to change.
CONTRIBUTING AUTHORS
Hillary Baldwin, MD
Kenneth Beer, MD
Brian Berman, MD, PhD
Brian Biesman, MD
Joseph Bikowski, MD
Barry Blass, MD
Michael Bukhalo, MD
Mitchel Chasin, MD
Joel L. Cohen, MD
Steven R. Cohen, MD
Karen Davis, MD
Nina Desai, MD
Cherie Ditre, MD
2
Lawrence F. Eichenfield, MD
Alan B. Fleischer, Jr., MD
Joseph Fowler, MD
Dore Gilbert, MD
Richard G. Glogau, MD
Michael Gold, MD
Linda Stein Gold, MD
Gary Goldenberg, MD
Mitchel P. Goldman, MD
Roy C. Grekin, MD
Pearl E. Grimes, MD
Jeffrey Henning, MD
Bruce Katz, MD
Steven Kempers, MD
Evan Leibowitz, MD
Christine Liang, MD
Rebecca Lu, MD
Mary P. Lupo, MD
Gilly Munavalli, MD
Vic Narurkar, MD
Chris Nelson, MD
Perry Robins, MD
Theodore Rosen, MD
Neil Sadick, MD
Ritu Saini, MD
Deborah Sarnoff, MD
Joel Schlessinger, MD, FAAD,
FAACS
Sejal Shah, MD
Stacy R. Smith, MD
James Spencer, MD
Monika Srivastava, MD
Hema Sundaram, MD
Wil Tutrone, MD
Jennifer Williams, MD
Debbie Zell, MD
William T. Zempsky, MD
The Derm Directory 2012
Media Kit 2012
OVERVIEW : WHAT’S IN IT FOR YOU
The Derm Directory is a point-of-care reference that builds brand awareness, generates leads, and establishes
your company as a key supporter of a highly-requested educational resource.
Reach the entire dermatology community during crucial decision-making moments with premium listings,
advertising, and sponsorship options.
„„ Premium Listings: Highlight your brand with a full-page product spotlight in the most comprehensive
dermatology reference guide
„„ Custom Sponsorships: Provide an invaluable resource to practitioners through customized conference
distribution, direct mailing to key prescribers, hand-delivery by your sales representative, and branded
smartphone/tablet apps
„„ Multi-media Platforms: Effectively deliver your message in print, online, and via smartphone
A CREDIBLE RESOURCE FOR DERMATOLOGISTS
The Derm Directory serves as a complete compendium of therapeutic and cosmetic modalities with information
on drugs, devices, injectables, skin care, and sunscreens.
Like the Physicians’ Desk Reference (PDR®), The Derm Directory is kept and referred to throughout the year and it
plays a direct role in product selection at the time of treatment. It includes every dermatology product available in
the United States within the following 5 categories:
„„ Drugs (Rx only)
„„ Devices
„„ Injectables
„„ Skin Care
„„ Sunscreens
98%
of doctors
surveyed
said The Derm Directory
would influence their
prescribing habits
AUDIENCE AND REACH
The Derm Directory reaches ≈14,500 dermatology
healthcare professionals including:
„„ Dermatologists
„„ Residents & Fellows
„„ Physician Assistants
„„ Nurse Practitioners
New for 2011
„„ Drug Peri-procedure
Considerations Chart
„„ Revised Device Categories
Coming in 2012
„„ Facial Moisturizers with
SPF Section
DISTRIBUTION
Available:
Print Launch: March 2012, AAD’s
70th Annual Meeting
Mobile: March 2012, AAD’s 70th Annual
Meeting (pending sponsorship)
Print Fulfillment: March - May 2012
Sponsorship opportunities to practitioners outside of the field
of dermatology are available; contact an Account Executive for
more information.
The Derm Directory 2012
3
Media Kit 2012
THE DERM DIRECTORY: FEATURES & CONTENT
NeoStra
ta Comp
skin active
hbeam
s
s Xv
hshape
rus Hr
solera
Opus
solera
titan
injec
sola
o Xl
sopran
500
care
tar r
tattoos
tar Y
tattoos
tM
ge cPt
therma
scan
therma
rm
transde
trios
el
ultrape
e
ultra Puls
reens
ies
varia
varilite
ns
vectra
M3
pe ii
velasha
s5
velure
s9
velure
contact
mfr.
erm
vibrad
suns
viridis
60
79, 87
57, 67,
includes
a wide rang
products
e of ther 72
apeutic
to
including treat a variety of
cond
aged skin
89 ition
s
acne, psor
, hyperpig
men
iasis, pho
to damage, 80tation,
chronic
dry skin
and
. Products
comedo
are non64
genic and
some are
for sens
itive skin
formulate 77, 85
. Total #
56,d
of products
:4
80,
55, 75,
includes
a wide rang
82, 88
products
e of ther
apeutic
to
including treat a variety of
condition 68
aged skin
s
acne, psor
, hyperpig
mentatio
iasis, pho
n, 62
to damage,
chronic
dry skin
and
. Products
comedo
85
are non77,
genic and
some are
for sens
itive skin
formulate
. Total #
70
of products d
:5
89
2011 Skin
Co-Cha
irmen
$76.00
Andrew
MPH, FAF. Alexis, MD,
AD
$199.00
faCulT
y
indd 114
1/14/11
2:19 PM
ory 201
rm Direct
The De
ices
gs_Dev
2011 Dru
.indd
bles
_Injecta
CEO
Cultur
Laser
Washin
Go to Skin
Cheryl
ofColorSem
M.
inars.c
Zoe Dia Burgess, MD,
na
FAAD
Amy Mc Draelos, MD
M
Michael
, MD
Su
Jes
Director
y 2011
nscreen.
1
52
Elio
Director
Skin of Colo
r Center
St. Luke’sRoosevelt
and Beth
New York
Israel
, NY
78
_Care_Su
derma
contact
mfr.
73
114 The
Derm
venus-i
cree
$26.00$60.00
74, 91
sunsc
vbeam
SkinofC
1/14/11
52
To reg
olorSemi
1:00 PM
S12042
Filler Ad.in
dd 1
Online Version: TheDermDirectory.com
„„ JDDonline cross-promotion increases online traffic
„„ Automatic online listing
„„ Advanced search capabilities
„„ Reference articles directly linked to PubMed® abstracts
„„ Worldwide complimentary access among all
healthcare professionals
„„ “MyList” functionality: stores selected products of
interest by category for quick reference and side by
side comparison
4
lo
TreaTin
$15.50$38.00
brandMd
acne defe
system
nse
brandMd
age defe
nse
system
e
triactiv
uv ser
Skin of Co
MSrp
88
technolo
gy drive 74, 91
n, med
clinically
tested. Form ical grade,
62
extracts
58,
ulate
d with herb
and phys
iologicall
al
nutrient
y active
s. Total
57, 86
# of prod
ucts: 51
72
o HP
synchr
ie
synerg
light
ie elite
synerg
er
ta2 eras
ct
tar effe
tattoos
care
skin
Neutrad
erm, inc.
neutrad
erm
877-252- .com
7546
brandMd
skin
inje
c ta b
les
sP Plus
starlux
CT liNE
Antiacne
drug
es
t HP
ide dO
ta b l e
ces
kin cO 2
hcool
prOdu
60
neostra
ta®
slimlipo
X
ipo MP
smartl
lex
ipo triP
smartl
smoot
ry wiTHiN
60
skintyte
smoot
Formulate
d
and utiliz for therapeutic
use
es
polyhydr key ingredients
such as
oxy acid
(PHa
lactobion
ic acid, and ) gluconolacto
ne,
care for
glycolic
specific
acid to
skin cond
offe
ition
88red. Total #
84,
of products s. kits are
55, 76,
: 10
adjunctiv
e
ther
apeutic
55, 82 that imp
products
rove the
visible sign
aging and
84
s of
65,
can trea
t acne, dry
hyperker
atos
skin,
61 more with is, skin discolor
ation, and
advanced
tech
hydroxy
85 nology inclu
acid
ding alph
acids (aHa
a-hydrox
s), polyhydr
y
64, 83
and
oxy acid
polyhydr
s (PHas)
oxy bion
also inclu
ic acids.
83
des Psor
line
ent® for
Total # of
psoriasis
products
.
63
: 34
Potent antia 70,
65,
formulate
56, 61, ging
of-the-ar
88
84,
d with state
ingredie
72, t76,
nts such
neogluc
as: patented
osamine™
78,
, apple stem
extract,57, 62, 70,
Peptides
cell
, chardon
seed extr86, 89
nay grap
act, glyc
e
olic
Polyhydr
76, 84 acid, retinol,
oxy/
64, bion
and
ic acids.
appeara
reduces
nce of deep
the
by build 60
lines and
ing derm
wrin
kles
al collagen
Please see
and gag
full73page
s.
details.
Total # of listing for more
products
77, 92
:4
91
59, 74,
62
sinon
smoot
CATEgO
KEy fEA
TurES
Antioxid
ant
Chem
ical
Peel
Clea
nser
Em
ollie
nt
Exfo
liato
r
Eye
Trea
tmen
Fine
t
Line
Repa
Gro
ir
wth
Fact
or
Pigm
ent
Redu
Pre/
cer
post
Proc
edur
Retin
e
ol
Scar
ring
Suns
cree
n
ta
Compan
y
neostrata 72
.com
78, 92
800-225941167,
, inc.
86
ticals® 62,
l
smartX
Wrinkle Reduction
Leg Veins
COMpAN
y/
prOdu
CT liNE
#
NeoStra page
neoceu
silkPee
smarts
raderm
age
Tattoo Removal
Skin Resurfacing
Skin Rejuvination
Psoriasis & Vitiligo
Pigmentation &
Vascular Lesions
Hair Reduction
Body Contouring,
Cellulite & Tightening
Acne
Non-Laser Light
Microdermabrasion
Intensed Pulse Light
(IPL)
Imagine System
e
CO2 – 10,600 nm
DeviC
Nd:YAG – 1320 nm
Nd:YAG –1064 nm
Diode – 800 nm
Pulse Dye Laser –
595 nm
Ruby Laser – 694 nm
Alexandrite – 755 nm
Type of
Er:YAG – 2940 nm
t
devic
T
KTP – 532 nm
Excimer Laser – 308 nm
s
drug
UC
proD
devi
„„ Section comparison tables for comparative
product assessment
„„ Company contact information
on Char
mparis
Co
Device
Radiofrequency (RF)
& Us
Tions
inDiCa
„„ 5 product categories: Rx Drugs, Devices,
Injectables, Skin Care, and Sunscreens
„„ Descriptive visual legends for general
information on each product
any - Ne
ut
s
Print Version
The Derm Directory 2012
iSTer
nars.co
m
Media Kit 2012
THE DERM DIRECTORY: CONTENT & FEATURES
xample of
E
General Listing
®
atralin
ical
(tretinoin)
45 g
the
ted for
05% gel,
is indica
s of age
10 year
ralin Gel
age: at
patients
uS
in
D
is
an
ar
vulg
® (clindamycin
ionS
ne
at
ac
iC
D
of
in
t
2%
phate 1.
mmon
treatmen
most co
ycin phos
topical
nS: the
: clindam
r.
dry skin,
DiCatio
r the
PPLieD
include
and olde
ntrain
this can
cated fo or
HoW Su
di
n.
Co
e side
in
D
tio
es
is
g
th
ita
an
l, 50
CtS
a Gel
me of
skin irr
years
fe
so
is
ny
l
12
ef
g.
ca
s
2.5% ge
e
ge
in
A
D
nt
el
atralin
e:
lin
Si
in patie
D uSag
with atra ssive flaking or pe r you have used
vulgaris
e effect
me a
te
ionS an
ce
af
co
sid
ne
at
ex
ss
be
ac
iC
s,
le
s
D
u
ct
es
of
in
e effe
ther yo
g, redn
nical
while,
tment
sid
in
bo
cli
e
ea
rn
d
tr
or
es
l
l
bu
lle
th
ay
ro
ge for a
topica
doctor if
ay go aw
g atralin
S: in cont curred in
effects m
. tell your
stop usin
iCation
you use
oc
ks
D
to
ee
ve
ns
n
u
older.
w
ha
ai
tio
yo
w
ntr
ask
tions
e reac
r a fe
ing, or
n-site
ay
rs
Co
fo
ac
us
l
m
tio
D
ve
re
e
ge
e
or
ica
ar
ad
an
rs
ct
pl
u
e
l: ap
adve
feCtS
. Your do of atralin gel yo
ication-sit
tionacanya ge
SiDe ef
t common rred within the
problem
ing appl
the mos
cu
amount
ated with .1%), and applica ous
e follow
not
ce a day.
(0
tients tre
in, and oc
ne
ange the
trials, th
ld
n
on
ta
sk
pa
ch
ou
e
tio
cu
an
of
sh
th
lia
th
l
ed
0.2%
l less
e exfo
tion of
ralin ge
re
perienc
ng,
less than
atralin ge moderate irrita
ication-sit
or stingi
s who ex
lin gel. at potential for seve
%), appl
to
ing, and/
e patient
with atra
pain (0.1
as wind
cases
ng, burn
were mild ks of treatment
in due to
%). Of th
ch
hi
.1
of
sk
su
(0
d
itc
,
ity
n
es
g,
ne
or
tio
extrem
sunbur
t, and
w wee
a, scalin
the maj
fe
er
d
m
or
en
y,
site irrita
s
th
st
te
m
he
ap
fir
ou
ea
at
ec
yt
er
at
prot
ith w
s of er
rly in tre
ith a
hip to th
on eczem
avoid un
lin gel w
symptom
tients w
curred ea
relations
be used
e of atra
ial for
irritation.
verity, oc raindicated in pa ssociated
ss of the
avoid us
creased
to potent
ate in se
regardle
-a
nt
and
ial for in
irritation.
gel due
to moder
gel is co
antibiotic rted with
t sPF 15
to potent
g atralin
as
e
in
le
du
us
at
were mild ereafter. acanya rative colitis, or
n
po
ld
if
whe
en re
or co
een of
ht
cr
be
th
ce
caution
ig
ns
d
ul
ve
nl
su
if
se
ith
is,
su
ha
e
d
w
gel
re to
n. us
decrea
ende
nts
enterit
colitis
lin
su
m
tio
d
al
ra
m
po
iza
an
on
at
,
co
ex
sit
gi
n.
e
re
ea
in
re
ei Patie
en
us
uation is
dy diarrh
fish prot
posure.
applying
d photos
history of
care
increase
enicity to
rhea, bloo amycin. discontin advised to avoid
during ex
th
g
ar
rg
ng
al
in
le
di
wi
al
th
he
is.
r
llo
r
colit
t thei
s are
tive clo
sure fo
l clind
ntial fo
nt
ac
ec
po
te
ca
nt
tie
ot
pi
ex
po
co
n
pr
Pa
to
.
to
ld
su
ou
fish due
the use of arrhea develops and to minimize
ticaria sh
allergic to
t di
lips,
itus or ur
euticals
significan , or nose, or on
lop prur
als
Pharmac
es
who deve
maceutic
valeant
mouth, ey n of acanya gel.
ant Phar
le
.
va
er
vision of
id
of
di
tio
prov
ries, a
division
to
a
ra
s,
the applica
bo
rie
to
a la
a labora
ny: cOri
om
ny: cOri
ComPa
ralingel.c
l.com
ComPa
erica
.com at
acanyage
erica
north am
corialabs
labs.com
north am
37
ria
19
co
61937
800-55
800-556xide
oyl pero
and benz
de)
nzoyl peroxi
phosphate-be
acanya
H oW
eD: 0.
SuPPLi
Information on All FDA-approved Rx Drugs, Devices, and
Injectables in Dermatology and All Physician-dispensed
Skin Care and Sunscreen Product Lines
s
evice
drug
s
p
acne: to
d

aczone
bles
®
d 60 g
l, 30 g an
e
ted for th
is indica
ge
LieD: 5%
are
skin c
reens
PPLieD
Benzac
HoW Su
• Lists: How Supplied, Indications and Usage, Shelf Life,
Duration, Side Effects and Contraindications, and Company
Contact Information
• Organized by therapeutic categories such as “Dermal Fillers”
INJECTABLES
sunsc
DEVICES
)
Premium product listing with
expanded information
atment of
for the tre
dicated
elex is in is.
age: az
ar
uS
lg
D
vu
ionS an
ory acne
cts may
inDiCat erate inflammat
g,
side effe
od
sh, peelin
ationS:
mild to m
ainDiC
hema, ra
ng
D Contr ng, tingling, eryt actions, worseni
an
S
feCt
rgic re
g, stingi
le
in
s,
al
rn
ot
SiDe ef
s,
sp
iti
bu
ted
rmat
en
uritus,
de
t
pr
gm
ac
pi
de
es
nt
all de
inclu
herp
s, co
dermatiti
recurrent
tation, sm
irritation,
depigmen exacerbations of
a, vitiligo
g, and
of asthm
reddenin
is,
os
ich
hypertr
labialis.
rgan, inc.
ny: alle
m
ComPa
lergan.co
4500 al
714-246-
HoW Su
g
ment, 25
for the
: 2% oint
dicated
ycin is in
e: akne-m
ag
uS
anD
S
n
ay
io
effects m
inDiCat
vulgaris.
nS: side
s,
t of acne
DiCatio oily skin, pruritu
treatmen
ntrain
a,
m
Co
he
D
yt
an
s, er
zer.
feCtS
g, drynes
d sensiti
SiDe ef
g, peelin
atitis, an
in
euticals
rm
rn
ac
de
m
bu
t
include
ant Phar
e, contac
n of vale
l resistanc
a divisio
bacteria
ratories,
bo
la
a
ny: cOri
ComPa
erica
m
north am
rialabs.co
1937 co
655
080

• Lists: Company Contact Information, Type of Device,
Indications and Usage, Wavelength, Energy Output, Pulse
Duration, Cooling, and MSRP
• Organized by therapeutic categories such as “Rejuvenation
(Nonablative)” or “Hair Reduction”
• Comparison chart: Type of Device and Indications & Usage
® (azelaic acid)
azelex : 20% cream, 30 g and 50 g
(erythromycin
PPLieD
(tretinoin)
LieD
oW SuPP
L
®
ycin
akne-m
HoW Su
oz
®
oxide)
aC (benzoyl per gel, 60 g; 5% and 10% wash, 8 atment
PPLieD
e tre
10%
ted for th
: 5% and
is indica
nzac ac
age: be
D uS
ionS an
inDiCat aris.
lg
of acne vu
1/14/11
1:19 PM
2011
.indd 12
jectables
vices_In
ugs_De
Generic equivalent
SKIN CARE
ory
rm Direct
New
product,
FDA-approved
12 The De
since 2009
2011 Dr
• Lists: Company Contact Information, Product Line, Key Features,
Category Within Product Line, and MSRP
• Organized alphabetically by company name
Use in lactating women is
“safe” or “probably safe”
FDA-approved for pediatric
use (≤11 years)
FDA-assigned pregnancy
category
The Derm Directory 2012
SUNSCREENS
L
g
g and 45
cream, 20
atment of
gel and
: 0.025%
for the tre
d
te
ca
di
H
avita is in
uSage:
D
an
de skin
S
ion
cts inclu
inDiCat is.
side effe
ar
ationS: king or peeling.
acne vulg
ainDiC
fla
tr
n
ive
ss
Co
D
exce
feCtS an rning, redness,
SiDe ef
bu
dry skin,
als, inc.
irritation,
maceutic
ar
Ph
n
ny: Myla
ComPa
ylan.com
9526 m
800-796-
avita
®
t of
treatmen
PP
e: aczone
D uSag
ionS an
d
nings an
inDiCat is.
s
nS: War
ar
DiCatio one treatment ha and
acne vulg
ntrain
ps
Co
da
signs
D
if
al
.
Or
ia
an
effects:
feCtS
ic anem
l
yt
ef
ica
ol
e
l
m
D
og
Si
ge 5%
atol
d he
r, aczone
ns: Hem
nts
olysis an
ted hem
Precautio
emia occu t be used in patie
dose-rela of hemolytic an
no
ld
ou
cause of
sh
e
produced
ggestiv
gel 5%
tions be
su
ne
ica
s
zo
5%
ed
l
om
m
ac
ued.
sympt
alarial
zone ge
discontin
e or antim mbination of ac
the
should be ng oral dapson
increase
ns. co
taki
ic reactio
ost
sMX) may
who are
y. the m
r hemolyt hoxazole (tMP/
nc
fo
l
ie
ia
fic
nt
) are
Pd de
famet
0%
ul
g6
the pote
/s
≥1
ith
im
w
ce
ciden
ethopr
tients
m
(in
pa
tri
in
5%
l
is
ith
e.
w
ge
olys
n sit
d of hem
of aczone at the applicatio
likelihoo
reactions
ma
adverse
d erythe
common
yness, an
eling, dr
pe
s/
es
oilin
ne.com
rgan, inc.
ny: alle
m aczo
ComPa
lergan.co
4500 al
714-246-
HoW Su
ta
injec
(dapsone)
DRUGS
• Lists: How Supplied, Indications and Usage, Side Effects and
Contraindications, and Company Contact Information
• Organized by therapeutic categories such as “Acne: Topical”
• Comparison chart: Active Ingredient, Company, Pediatric Age,
and Pregnancy Category
• Lists: Company Contact Information, Product Line, Key Features,
SPF: Active Ingredients, Category Within Product Line, and MSRP
• Organized alphabetically by company name
5
Media Kit 2012
PREMIUM LISTING: EXAMPLE
Premium Listings
Stand out from your competitors with a visually-enhanced and clinicallyrelevant full-page product listing dedicated exclusively to your product!
„„ Clinical References
„„ In-depth Product Descriptions
„„ Clinical Pearls and Key Features from a KOL
„„ Influential Physician Commentaries
Secure Your
Premium
Listing Toda
y
Ways To Maximize Your Premium Listing:
Product recognition
pical
eratosis: To
and awareness
r & Actinic K
Skin Cance
®
d) Cre
Zyclara (imiquimo
drugs
am, 3.75%
clinical Pe
devices
bles
nt
the treatme
and 3.75% for
face
ArTiCleS:
uimod 2.5%
lication to the
b, et al. imiq
ies of daily app
W, berman
trolled stud
82-590.
n, abramovits
. 2010;62(4):5
2 placebo -con
of
atol
1. swanson
lts
Derm
resu
d
toses:
actinic
es. J Am Aca
of actinic kera
clearance of
2-week cycl
th sustained
scalp for two
lied
and balding
al. twelve mon
and 3.75% app
of
berman b, et
uimod 2.5%
n academy
n, Hanke cW,
p after imiq
68th america
2. swanson
or balding scal
presented at:
ter
the full face
of
Pos
s
es.
tosi
cycl
kera
mi, Fl.
eek or 3-week
Mia
2-w
zed,
;
omi
two
2010
for
ch
a rand
; Mar
daily
g t, lev y s.
ual Meeting
Men
j,
%
ann
y
3.75
kulp
of
olog
dermat
bourcier M,
safety study
lebwohl M,
, efficacy and
s. J Drugs
Markowitz O,
multicenter
nic keratose
3. jorizzo j,
-controlled,
tment of acti
ded, placebo
ery for the trea
double-blin
wing cryosurg
cream follo
imiquimod
08.
1-11
;9(9):110
Dermatol. 2010
skin care
ens
ry:
rapy for
n for field the
ients
ellent optio
lly use it in pat
am is an exc
(ak). i typica
“Zyclara cre
in my
inic keratosis
cryosurgery
act
ing
h
low
wit
ts
fol
ll
patien
dies and
works we
stu
it
l
ica
and
’s
clin
ak
in
le
efficacy
erm
with multip
, two
g-t
off
lon
excellent
on, two weeks
practice. it has
of two weeks
atment course
a simple tre
erg, MD
week on.”
Gary Goldenb
ogy
y and Pathol
log
ato
rm
fessor, De
Assistant Pro
of Medicine
ool
Sch
ai
Mount Sin
New York, NY
referenCe
CompAny:
s, llc
armaceutical
graceway Ph
800-328-0255
m
aypharma.co
www.gracew
cream.com
www.zyclara
petent adults.
ion or
immunocom
edema, eros
ing scalp in
ing or dryness,
full face or bald
rruptions
flaking, scal
s (ak) of the
dosing inte
or crusting,
s can occur.
hema, scabbing emic signs and symptom
eryt
ded
inclu
ike syst
tions
nt of clini
. these reac
s and/or flu-l
tme
area
tion
trea
ion
reac
cal
y
licat
ator
s in the app
d for the topi
local inflamm
m is indicate
skin reaction
erate. intense
Zyclara crea
effects involved
as mild to mod
t common side
s were rated
cream.
ies, the mos
t skin reaction
use of Zyclara
in clinical stud
exudate. Mos
imized during
weeping or
avoided or min
be
ld
ulceration, and
shou
nt)
ired.
uva/b treatme
or
s
bed
may be requ
t (tanning
icial sunligh
cent page.
natural or artif
tion on adja
exposure to
ing informa
Full Prescrib
f summary of
Please see brie
visible or
cally typical
nic keratose
1
Directory 201
44 The Derm
©2010 Graceway Pharmace
uticals, LLC, Bristol, TN
www.gracewaypharma.com
www.ZyclaraCream.com
ZYC031093
TheDermDirectory.com
6
Change th
of AK treat
palpable acti
sunscreens
sunscre
drugs
cOMMenta
Prescribing information
summary printed
adjacent to listing for
easy reference
i n j e c ta b l e s
i n j e c ta
Skin Cancer & Actinic Kera
tosis: Topical
devices
Age:
of clinically
nS And uS
l treatment
indiCATio
for the topica
full face or
is indicated
ses (ak) of the
Zyclara cream palpable actinic kerato
or
adults.
t
ten
pe
typical, visible
in immunocom
balding scalp
nS:
rAindiCATio
ma, edema,
S And ConT
ctions, erythe
Side effeCT
usting and
local skin rea
, scabbing/cr
may include
ess
s
ect
ryn
eff
g/d
e
sid
e headache,
ing/scalin
lud
flak
,
inc
ate
ns
ud
ed reactio
ort
weeping/ex
on adjacent
rep
n
er
atio
Oth
ration.
ibing inform
erosion/ulce
er. see Prescr
sea, and fev
fatigue, nau
page.
re
skin ca
y Features:
rse
a simple cou
ly dosing in
» Once-dai
/ 2 weeks on
/ 2 weeks off
on
eks
we
• 2
1
can’t
the ones you
can see—and
lesions you
ted lesions
» treats the
usly undetec
vio
pre
had
ients
• 86% of pat
treated
revealed and
ained clear
lara cream rem
ared with Zyc
wh
ients o cle
nt1
cou
ion
» Many pat
les
ion in overall
• 82% reduct
nce1
plete cleara
ients had com 1
• 36% of pat
the
tial clearance
par
had
reduction in
• 59%
ed as >75%
arance defin
– Partial cle
s at baseline
ion
les
of
er
lesion
numb
nce remained
plete cleara
2
ients with com
nt
me
• 40% of pat
eat
nths posttr
free at 12 mo
of cream
lied:
tain 250 mg
How Supp
kets which con
single use pac
a box of 28
Optional before
and after photos
and clinical data
tables/graphs
arls and ke
Please see important safety inform
ation
45
The Derm Directory 2012
on
Media Kit 2012
PREMIUM LISTING: COST-EFFECTIVE MARKETING
Added Value
„„ Red starburst
distinguishes your
product among the general listings and
in the comparison table
„„ Inclusion in the print and online
Buyer’s Resource Guides for year-round
lead generation
„„ On TheDermDirectory.com, premium
listings are highlighted and listed before
general listings
„„ Conference distribution and promotion at
Orlando Dermatology Aesthetic & Clinical
(ODAC) conference, ASDS Annual Meeting,
and the AAD Meetings
„„ Direct link to your website from
TheDermDirectory.com
Additional Product Advertising
„„ Corporate or Product Advertisement
„„ Cover Shot
„„ Cover-tip or Belly-band
„„ Custom Insert (CD-ROM, BRC, Newsletter)
„„ Online Banner Advertisements
„„ 10 complimentary copies of The Derm
Directory
Sponsorship Opportunities
„„ Exclusive Smartphone/Tablet App:
Reach a hot, new market of mobile
users—expected to rise to 81% of
physicians by 2012
„„ Conference Distribution: Hit the market
first with the launch of the 2012 Edition
of The Derm Directory at the AAD Annual
Meeting
„„ Sales Representative Direct Delivery:
Give your sales reps a great reason to call on
HCPs with a premium drug reference tool
„„ Online Premium Listing
„„ Online Video Pearls
„„ Direct Mailing Fulfillment: Gain premium
exposure by supporting the mailing of The Derm Directory 2012 to ≈14,500
dermatology healthcare professionals
HOW IS THE DERM DIRECTORY DIFFERENT
FROM OTHER ADVERTISING?
„„ Shelf Life: Generates leads for 12 months
„„ Unique Content: Comprehensive product information that is in demand
„„ Targeted Circulation: Reaches a dermatology community of ≈14,500 practitioners
„„ Motivated Readership: Year-round promotion yields strong anticipation among healthcare professionals
„„ Online Directory: Free, unrestricted online and mobile availability ensures easy, everyday accessibility
„„ Extended Visibility: Reach plastic surgeons and other aesthetic specialists with online platforms
The Derm Directory 2012
7
Media Kit 2012
DON’T BE LEFT OUT IN 2012
Pricing and material specifications can be found on the enclosed 2012 Rate Card.
FULL PAGE PREMIUM LISTINGS IN THE DERM DIRECTORY
Reserve
Your Premiu
m
Listing
Placement
Today!
Acanya®
Efudex®
Neutrogena Clinical™
Aczone®
Elastiderm®
Neutrogena® Rapid Wrinkle Repair
Affirm™
Elastiderm™ Décolletage System
Neutrogena® Spectrum Plus Sunblock
Solar Protection Formula®
Affirm CO2™
Elite MPX™
Obagi® Condition & Enhance
Solaraze® Gel
Aldara®
EndyMed PRO™ with 3Deep™
Obagi-C® Rx
Solodyn®
Altabax®
Epiduo®
Obagi Nu-Derm®
SoluCLENZ Rx Gel™
ArteFill®
Epiquin® Micro
Olay® Pro-X Intensive Firming Kit
Soriatane®
Atralin®
Ertaczo®
Olay® Pro-X Intensive Wrinkle Protocol
Sotradecol®
Aveeno® Eczema Therapy
Extina®
Olay® Regenerist
Starlux® 500
Aveeno® Natural Protection
Mineralblock
Fraxel re:fine®
Olux-E®
Tazorac®
Aveeno® Skin Relief
Fraxel re:pair®
Oracea®
Tersi Foam
BenzaClin®
Fraxel re:store® Dual Laser
Oxistat®
Thermage CPT™
Botox® Cosmetic
Gemini®
Pearl™ Fractional
Thermage® NXT System
Cleanse and Treat®
GentleMax®
PoxiDerm™
Topicort®
CLENZIderm M.D.™
Isolaz™ Deep Pore Lazer Therapy
PRN®
Tretin-X™
Clobex® Spray
LidoSite®
Protopic®
Vaniqa®
CoolLipo™
LipoLite™
Renova®
VelaShape™
Cutivate®
Locoid Lipocream®
Retin-A Micro®
Velashape™ II
Cutera Xeo™
Locoid® Lotion
Rosaclear™
Verdeso® Foam
DermaSweep MD™
Minocin®
Sapphire Abrasion
Veregen™
Dermatix™ Ultra
Naftin®
Skin™ by Nulastin
Vusion®
Dermatologic Cosmetic Labs®
NeoBenz® Micro SD
Smartlipo™ MPX
Xeo™
Desonate®
NeoBenz® Micro Wash
Smartlipo Triplex™
Xolegel®
DUAC® Topical Gel Care System
Neocutis® Skin Care Lines
SmartSkin CO2™
Zyclara®
eSeries™
NeoStrata Skin Active
SmartXide Dot™
All FDA-approved/cleared products are automatically listed; however, please expect to hear from us as we reach out to ensure
all of your products are listed accurately. Please be sure to update your general listing information by November 18, 2011.
DEADLINES
Early Space Reservation Special
7/21/2011
(5% discount on all Premium Listings)
8
Space Reservation
10/21/2011
Premium Listing Materials Due
10/31/2011
Launch Date
3/16/2012
TO SECURE PLACEMENT OR FOR MORE
INFORMATION ABOUT SPONSORSHIP
OPPORTUNITIES, CONTACT:
LUZ FIGUEROA
Account Executive
[email protected]
(646) 736 4338 — office
(949) 760 0522 — fax
The Derm Directory 2012